Project Grant HT9425261E354
Award Date 7/15/26
Completion Date 7/14/29
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $723,699 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 15, 2026, through July 14, 2029. The award supports research aimed at optimizing immunotherapy for pediatric solid tumors. Based on DHA's funding portfolio and Dana-Farber's research capabilities, this project likely involves mechanistic studies and...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1.12M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2030. The award supports resource development and research to improve clinical outcomes for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic malignancy. As a leading academic cancer research institution affiliated...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1.424 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded August 1, 2025, with a performance period through July 31, 2029. The award supports research to expand the targetable tumor antigen repertoire of renal cell carcinoma, positioning the work within DHA's broader portfolio of hypothesis-driven biomedical research...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $4.199 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2026 through August 31, 2030. The award funds the development and optimization of B7-H3 chimeric antigen receptor (CAR) T cells for pediatric and young adult patients with sarcomas and other B7-H3-positive solid tumors. This research initiative represents an...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $559,999 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to support the development of novel digenic combination therapies for pancreatic cancer treatment. The award period runs from September 1, 2026 through August 31, 2028. This funding supports basic and applied biomedical research addressing medical needs relevant to the military population,...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1,099,614 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective June 1, 2026 through May 31, 2030. The award funds research to define a Retinoblastoma (RB) functional subtype of endometrial cancer. This research initiative aligns with the DHA's mission to support basic and applied biomedical research addressing Service Member...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.1 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026, through May 31, 2030. The project, titled "LISTEN: Augmenting and Facilitating Communication in Brain Tumor Patients with Aphasia," supports biomedical research addressing Service Member health and military-relevant medical conditions. The four-year...
- The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
- The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $752,238 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2026 through June 30, 2029. The award supports the development and validation of explainable artificial intelligence (AI) methodologies for predicting melanoma progression and survival outcomes. This three-year initiative aligns with the DHA's mission to...